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Abstract
Epidemiological and genetic studies have identified metabolic disorders and inflammation as
risk factors for Alzheimer’s disease (AD). Evidence in obesity and type-2 diabetes suggests a
role for a metabolic inflammasome (“metaflammasome”) in mediating chronic inflammation
in peripheral organs implicating IKKb (inhibitor of nuclear factor kappa-B kinase subunit
beta), IRS1 (insulin receptor substrate 1), JNK (c-jun N-terminal kinase), and PKR (double-
stranded RNA protein kinase). We hypothesized that these proteins are expressed in the brain
in response to metabolic risk factors in AD. Neocortex from 299 participants from the MRC
Cognitive Function and Ageing Studies was analysed by immunohistochemistry for the
expression of the phosphorylated (active) form of IKKb [pSer176/180], IRS1 [pS312], JNK
[pThr183/Tyr185] and PKR [pT451]. The data were analyzed to investigate whether the
proteins were expressed together and in relation with metabolic disorders, dementia,
Alzheimer’s pathology and APOE genotype. We observed a change from a positive to a
negative association between the proteins and hypertension according to the dementia status.
Type-2 diabetes was negatively related with the proteins among participants without
dementia; whereas participants with dementia and AD pathology showed a positive
association with JNK. A significant association between IKKb and JNK in participants with
dementia and AD pathology was observed, but not in those without dementia. Otherwise,
weak to moderate associations were observed among the protein loads. The presence of
dementia was significantly associated with JNK and negatively associated with IKKb and
IRS1. Cognitive scores showed a significant positive relationship with IKKb and a negative
with IRS1, JNK and PKR. The proteins were significantly associated with pathology in
Alzheimer’s participants with the relationship being inverse or not significant in participants
without dementia. Expression of the proteins was not related to APOE genotype. These
findings highlight a role for these proteins in AD pathophysiology but not necessarily as a
complex.
INTRODUCTION
The number of people living with dementia is estimated at 35.6
million persons with the number to double by 2030 and triple by
2050, costing already $604 billion in 2010 according the WHO and
the Alzheimer’s Disease International (1). The major cause of
dementia is Alzheimer’s disease (AD) which is responsible for
about two thirds of cases. AD pathology is characterised by the
accumulation of amyloid-b peptide (Ab) plaques, hyperphosphory-
lated tau protein within neuronal somata and processes, neuroin-
flammation and neuronal loss. However, Ab and to a lesser extent
tau accumulation are also frequently observed in the brains of non-
demented persons (2). This suggests that key features of AD are
neither necessary nor sufficient for the development of cognitive
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failure, even in the absence of other dementia-associated pathology.
In contrast, systemic inflammation (3) and tangle pathology (4) cor-
relate closely with cognitive decline, but the underlying biological
mechanisms are poorly understood. The heritability of AD is
between 0.6 and 0.7 (5–7), and a long established genetic risk fac-
tor for AD is polymorphism of the apolipoprotein E (APOE) gene
(8, 9). More recently, large-scale genome-wide association studies
(GWAS) have clearly implicated genetic variation in innate immu-
nity and other aspects of lipid metabolism (10–12). In addition, sev-
eral environmental risk factors for AD currently of great
importance in the field of public health include type 2 diabetes
(13–15), obesity (16–18), midlife hypertension (19–21) and sys-
temic infection (22). Interestingly, these environmental risk factors
are all associated with disorders of lipid metabolism and/or the
induction of chronic low-grade systemic inflammation (23–25).
The inflammasome is a multiprotein complex expressed in mye-
loid cells and a component of the innate immune system responsi-
ble for activation of inflammatory processes (26). Experimental
studies implicate involvement of the inflammasome in the initiation
or progression of diseases with an impact on public health, such as
metabolic disorders and neurodegenerative diseases (27). Based on
the concept of the inflammasome, a metabolic inflammasome or
“metaflammasome” has been introduced to describe the cellular
signaling reaction observed after stress induced by misfolded pro-
tein in the endoplasmic reticulum, lipid stress (eg, obesity, type 2
diabetes) or infection (28), linking together the metabolic disorder
and inflammation observed in periphery (29). Experimental studies
have identified the kinases IKKb (inhibitor of nuclear factor kappa-
B kinase subunit beta), IRS1 (insulin receptor substrate 1), JNK (c-
jun N-terminal kinase) and PKR (double-stranded RNA protein
kinase) as major contributors to the induction of inflammation in
tissue affected by metabolic disorders (28–30). In response to nutri-
ent or inflammatory signals, PKR becomes activated, leading to the
phosphorylation of JNK, IKKb and IRS1, resulting in inhibition of
the insulin receptor signalling cascade (28, 30). PKR and JNK are
also known to be involved in human AD with elevated PKR and
JNK detected in the cerebrospinal fluid (CSF) of AD patients and
their levels associated with the rate of cognitive decline (31, 32).
In this study, we hypothesize that these four proteins are
expressed in the brain together in response to metabolic risk factors
and are analogous to the metaflammasome complex described in
the periphery. We also tested whether the phosphorylated (active)
forms of these proteins were associated with (i) dementia status; (ii)
cognitive impairment; (iii) specific features of AD pathology and
(iv) APOE genotype. We have explored these hypotheses in the
large well-studied MRC Cognitive Function and Ageing Study
(CFAS) postmortem cohort.
MATERIALS AND METHODS
The CFAS cohort
The CFAS study involves six centres in the UK (Liverpool, Cam-
bridge, Gwynedd, Newcastle, Nottingham and Oxford). The design
and methods have been described in detail elsewhere (33). In brief,
the project began in the early 1990s and recruited individuals aged
65 years and over living in the community. The main aims were to
estimate the prevalence and incidence of cognitive decline and
dementia; to determine the rate of progression of cognitive decline
and survival, and to identify risk factors for cognitive decline and
dementia. Baseline prevalence screening of the cohort included
sociodemographic, cognitive, physical health and medication data.
Participants were asked to consent to brain donation after death.
The ascertainment of dementia status at death has already been
published (34) and was based on review of information available
from death certificate, last interview assessment and the informants’
information about participants’ function and cognition (mini mental
state examination—MMSE—score) during the last years of life. A
total of 299 brains were used in this study with the demographic
and cognitive profile of the cohort described in Table 1. In 21
cases, insufficient information was available for a diagnosis of
dementia to be made; these cases are included in pathological anal-
yses but excluded from the study of dementia interactions. In 15
cases, there were no available data regarding hypertension or type
2 diabetes. Among those with available information, 42% of the
participants had hypertension and 12% had type 2 diabetes, both
self-reported either by the participant, a relative or the career. The
study received ethical approval from the Cambridgeshire 1
Research Ethics Committee (Rec number: 10/H0304/61/).
Assessment of Alzheimer pathology
Pathological evaluation of the CFAS cohort has been previously
described (34) and was conducted by neuropathologists, blind to
Table 1. Characteristics of the cohort according to dementia status and metaflammasome components.
No dementia
(n5130)
Overall dementia
(n5148)
Dementia with
AD pathology
(n583)
Number of women (%) 66 (51) 102 (69) 53 (64)
Age at death† 84 (77–90) 89 (84–93) 89 (83–93)
Years since last cognitive assessment† 1.1 (0.5–1.8) 1.7 (0.8–3.1) 1.5 (0.8–3.2)
MMSE at last assessment† 25 (22–28) 14 (8–20) 11 (6–17)
IKKb load (%)†† 0.302 (0.002) 0.282 (0.002) 0.279 (0.003)
IRS1 load (%)†† 0.391 (0.003) 0.379 (0.003) 0.360 (0.003)
JNK load (%)†† 0.266 (0.005) 0.274 (0.003) 0.302 (0.004)
PKR load (%)†† 0.542 (0.005) 0.540 (0.005) 0.551 (0.006)
†Median, inter quartile range.
††Linearized mean (linearized standard error) expressed as protein load (%).
Taga et al. Metaflammasome Proteins in Alzheimer’s Disease
Brain Pathology 27 (2017) 266–275
VC 2016 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
267
clinical data, using immunohistochemical or tinctorial methods.
The severity of diffuse plaques, neuritic plaques and tangles was
scored semiquantitatively according to the Consortium to Establish
a Registry for Alzheimer’s disease (CERAD) protocol as either
“none,” “mild,” “moderate” or “severe.” For the analysis, the
scores were simplified as the score “severe” did not occur very
often. It was merged with “moderate,” and the score “mild” was
merged with “none.” Cerebral amyloid angiopathy (CAA) was
assessed in the meninges and parenchyma on a similar semiquanti-
tative scale. At the end of the assessment a final neuropathological
diagnosis of AD based on the distribution and severity of plaques
and tangles, but blind to any clinical information was made.
Immunohistochemistry
The following primary antibodies directed against the phosphoryl-
ated (active) form were used: rabbit anti-IKKb [pSer176/180] (Cell
Signaling, Hertfordshire, UK); rabbit anti-IRS1 [pS312] (Invitrogen,
Loughborough UK); rabbit anti-JNK [pThr183/Tyr185] (Cell Signal-
ing, Hertfordshire UK) and rabbit anti-PKR [pT451] (Invitrogen,
Loughborough UK) (Figure 1).
Four micrometer sections of formalin-fixed paraffin-embedded
tissue from the middle frontal gyrus, a region which is part of the
CERAD neuropathology assessment for the diagnosis of AD, were
used for immunostaining for microglial proteins. Immunohisto-
chemistry was performed using the appropriate antigen retrieval
methods for each primary antibody. Biotinylated secondary anti-
bodies were from Dako (Glostrup, Denmark), and normal serum
and avidin–biotin complex from Vector Laboratories (Peterbor-
ough, UK). Biotinylated antibody was visualized using the avidin–
biotin-peroxidase complex method [Vectastain Elite ABC from
Vector Laboratories (Peterborough, UK)] with 3,30 diaminobenzi-
dine [DAB, Vector Laboratories (Peterborough, UK)] as chromo-
gen and 0.05% hydrogen peroxide as substrate. All sections were
counterstained with haematoxylin then dehydrated before mounting
in DePeX (VWR International, Lutterworth, UK). Cases were
immunolabeled together in batches to ensure compatibility of stain-
ing and sections incubated in the absence of the primary antibody
were included as negative controls. For each antibody, a positive
control was included to ensure staining consistency across the dif-
ferent batch runs.
Quantification
Quantification was performed blind to the experimental group and
identity of the cases. Images of the slides were taken from the same
anatomical regions in every case as identified by a neuropathologist
(JN). For each antibody, 30 images of cortical grey matter at mag-
nification 320 were taken per case in a zigzag sequence along the
cortical ribbon to ensure that all cortical layers were represented in
the quantification in an unbiased manner. The acquired images
were analyzed using ImageJ (version 1.49m, Wayne Rasband,
NIH, USA), with a threshold applied to the image to select and
measure the total amount of specific immunostaining. The same
threshold setting was maintained to all images of all cases stained
for the same antibody and the area fraction of the measure function
provided the proportion (%) of the stained area related to the total
area of the image (expressed as protein load) (35). A macro was
designed to incorporate all the steps allowing automatic image
processing and data collection. The data were then sent to the
Department of Public Health and Primary Care for statistical
analysis.
Statistical analysis
The analyses were performed by Dr Minett and Prof Matthews,
Professor of Epidemiology and Principal Statistician on the CFAS.
Means (standard deviation) or median (interquartile range) are
reported. The Spearman correlation coefficients were calculated to
verify the strength of the relationship between IKKb, IRS1, JNK
and PKR expressions.
Their relationships with dementia status and frontal lobe neuro-
degenerative pathologies were verified using weighted logistic
Figure 1. A. Illustration of immunostaining of the metaflammasome
phosphorylated components: IKKb [pSer176/180] (inhibitor of nuclear
factor kappa-B kinase subunit beta), IRS1 [pS312] (Insulin Receptor
Substrate 1), JNK [pThr183/Tyr185] (c-jun N-terminal kinase), and PKR
[pT451] (Double-stranded RNA protein kinase) in human post-mortem
brain. B. Illustration of the number of cell-positive for each protein in a
participant with dementia and AD pathology. Haematoxylin counter-
staining; scale bar: (A) 20lm; (B) 100lm
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regression where the 30 images acquired for each microglial protein
were given the same 1/30 weight.
Weighted multiple linear regression analysis to assess whether
metaflammasome protein expression was related to hypertension,
type 2 diabetes and cognition (MMSE) after adjustment for the
interval between last interview and death.
To verify the association of APOE genotype with metaflamma-
some protein expression (dependent variables), weighted logistic
regressions were performed with e2 and e4 carrier status used as
independent variables regardless of the number of alleles, and with
both alleles simultaneously present in the analysis. Sensitivity anal-
yses were performed to verify if the relationships predicted by the
regressions were stable. For this, the metaflammasome component
loads were divided into quartiles and the categorised data used
rather than the raw scores into the weighted regression analyses.
All regression analyses were adjusted for age of death and sex.
All tests were 2-tailed and statistical analyses were performed using
the statistical package STATA, version 12. A P-value< 0.05 was
considered as significant, unless a potential problem of multiple
comparisons was identified, in which case, the critical P-values
were adjusted according to the Bonferroni’s method.
RESULTS
Characteristics of the cohort regarding
dementia status
Among the 299 participants, 148 (69%) cases had dementia at
death (Table 1) and for 21 (7%) cases the dementia status was
unknown. Of the 148 cases with dementia, 83 (56%) had plaques
and tangles sufficient for the diagnosis of AD as the cause of
dementia. For the participants without dementia, 66 (51%) were
women, the median age at death was 84 years (77–90) and the
median MMSE score performed at the last assessment was 25
(22–28). For the group with dementia, 102 (69%) were women,
including 64% with AD pathology, with median age at death of 89
years (83–93). The median MMSE score performed at the last
assessment for the dementia group was 14 (8–20) and 11 (6–17)
for people with dementia with AD pathology (Table 1).
Immunodetection of the metaflammasome
components in the brain
All four components of the metaflammasome: IKKb, IRS1, JNK
and PKR were detected by immunohistochemistry in neurons in
the cerebral cortex as illustrated in Figure 1A. For PKR and IRS1,
the staining was nuclear, cytoplasmic for IKKb, and present in
both neuronal compartments for JNK, as expected from the litera-
ture. The immunodetection shows a difference in the cell density
between the different metaflammasome proteins as illustrated in the
brain of a participant with dementia and AD pathology (Figure
1B). Interestingly, some of the participants without dementia did
not expressed JNK. The quantified protein load (%) for each pro-
tein used for the analyses is presented in Table 1.
Metaflammasome proteins and metabolic risk
factors for AD
We assessed the association of the expression of metaflammasome
proteins and two metabolic disorders known as risk factors for AD:
hypertension and type 2 diabetes.
Among participants without dementia, a significant positive rela-
tionship was detected between hypertension and IKKb, IRS1 and
JNK. In contrast, among participants with dementia and AD pathol-
ogy, all components of the metaflammasome were negatively asso-
ciated with hypertension (Table 2). Type 2 diabetes was negatively
associated with IKKb, IRS1 and JNK among participants without
dementia; whereas among participants with dementia and AD
pathology, a significant negative association was observed with
IRS1 and PKR, and a significant positive relationship with JNK
(Table 2).
Interaction of the metaflammasome proteins
The overall correlations between the metaflammasome proteins
were weak or moderate. Among participants without dementia, sig-
nificant positive correlations were detected except between IKKb
Table 2. Weighted multiple linear regression to investigate the relationship between metaflammasome components and hypertension and self-
reported type 2 diabetes.
Metaflammasome
components [load (%)]
No Dementia Dementia with AD pathology
b 95%CI(b) P b 95%CI(b) P
Hypertension
IKKb 0.02 (0.02; 0.03) <0.001 20.03 (20.05; 20.02) <0.001
IRS1 0.04 (0.03; 0.06) <0.001 20.03 (20.04; 20.01) 0.006
JNK 0.07 (0.05; 0.09) <0.001 20.05 (20.07; 20.03) <0.001
PKR 20.01 (20.03; 0.01) 0.281 20.09 (20.11; 20.06) <0.001
Type 2 diabetes
IKKb 20.02 (20.03; 20.01) 0.004 0.00 (20.02; 0.02) 0.793
IRS1 20.05 (20.06; 20.03) <0.001 20.05 (20.07; 20.02) <0.001
JNK 20.05 (20.07; 20.04) <0.001 0.10 (0.06; 0.13) <0.001
PKR 20.01 (20.04; 0.01) 0.225 20.07 (20.11; 20.02) 0.005
P-value< 0.012 considered to indicate statistical significance according to the Bonferroni’s method.
Significant positive association (dark gray); Significant negative association (light gray).
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and JNK. Among participants with dementia and AD pathology,
significant positive correlations were observed between JNK with
PKR and IRS1, and PKR with IRS1. A negative correlation was
detected between IKKb and JNK. There were no significant corre-
lations between IKKb with IRS1 and PKR (Table 3 and Figure 2).
Metaflammasome proteins, dementia status
and MMSE scores
Dementia status (ie, dementia vs. no dementia) and MMSE scores
were analyzed in relation to the metaflammasome proteins. First for
dementia status, we observed in the whole cohort after sensitivity
analysis, a significant negative relationship with IKKb, indicating
that the participants with low expression of IKKb were likely to
have dementia. The analysis in participants with dementia and AD
pathology revealed in addition to the significant negative relation-
ship with IKKb, a significant negative association with IRS1 and a
significant positive relationship with JNK. Thus, participants with
dementia and AD pathology are likely to have expression of rela-
tively higher levels of JNK and lower levels of IKKb and IRS1 rel-
ative to participants without dementia (Table 4).
Second, in relation to the MMSE score, we showed among the
whole cohort a significant positive relationship with IKKb and a
significant negative relationship with IRS1, JNK and PKR. There-
fore, good cognition was associated with higher IKKb expression
and lower IRS1, JNK and PKR expression (Table 5).
Metaflammasome proteins and AD
neuropathology
Among participants without dementia, the significant relationships
observed between metaflammasome proteins and AD neuropathol-
ogy were negative between: IKKb and meningeal CAA; IRS1 and
diffuse and neuritic plaques; and JNK and neuritic plaques (Table
6). The other relationships were not maintained in the sensitivity
analysis.
In the participants with dementia and Alzheimer’s pathology, the
significant maintained relationships were mainly positive and stron-
ger than those in the participants without dementia. IKKb expres-
sion was significantly related to diffuse and neuritic plaques. JNK
was strongly related with meningeal and parenchymal CAA and
neuritic plaques, and PKR with parenchymal CAA (Table 6). The
other associations were not maintained in the sensitivity analysis.
Figure 2. Cartoon to illustrate the interactions of the different
metaflammasome phosphorylated proteins in the human brain in
relation with the dementia status. A. In the absence of dementia,
positive associations (black arrows) are observed between JNK, IRS1
and PKR and between IKKb, IRS1 and PKR. No relationship is
observed between JNK and IKKb. B. In the presence of dementia
with Alzheimer’s pathology, relationship between IKKb with IRS1 and
PKR are lost and an inverse association (gray arrow) is formed
between JNK and IKKb.
Table 3. Correlation matrix of the metaflammasome components
[load (%)].
Correlation
No dementia Dementia with AD
pathology
r P r P
IKKb 3 IRS1 0.33 <0.001 0.15 0.171
IKKb 3 JNK 0.07 0.463 20.29 0.009
IKKb 3 PKR 0.25 0.004 20.13 0.260
IRS1 3 JNK 0.43 <0.001 0.30 0.006
IRS1 3 PKR 0.34 <0.001 0.38 <0.001
JNK 3 PKR 0.59 <0.001 0.66 <0.001
P-value< 0.008 considered to indicate statistical significance accord-
ing to the Bonferroni’s method.
Significant positive association (dark gray); Significant negative associ-
ation (light gray).
Table 4. Weighted logistic regression to analyse the relationship
between metaflammasome components and dementia.
Metaflammasome components [load (%)] OR 95%CI(OR) P
Dementia/no Dementia
IKKb† 0.2 (0.2; 0.3) <0.001
IRS1 0.5 (0.4; 0.7) <0.001
JNK 1.1 (0.9; 1.3) 0.338
PKR 0.9 (0.8; 1.0) 0.059
Dementia with AD pathology/no Dementia
IKKb† 0.2 (0.1; 0.4) <0.001
IRS1† 0.3 (0.2; 0.4) <0.001
JNK† 1.5 (1.2; 1.9) <0.001
PKR 1.0 (0.8; 1.1) 0.617
P-value< 0.012 considered to indicate statistical significance accord-
ing to the Bonferroni’s method.
†Significant positive association (dark gray) and significant negative
association (light gray) with the relationship maintained in the sensitiv-
ity analysis.
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Metaflammasome proteins and APOE
polymorphism
With regards to the APOE polymorphism, the expression of meta-
flammasome proteins did not change the dementia risk conferred
by the APOE genotype (data not shown).
DISCUSSION
Our data show that the four kinases (IKKb, IRS1, JNK and PKR)
are all expressed in the human brain. However, they might not act
as a metaflammasome complex as hypothesized in experimental
metabolic disease (30), due to the absence of some associations, the
weakness of the observed correlations and the difference in the cell
density expressing the proteins. Nevertheless our findings highlight
a role for these proteins in association with metabolic disorders (eg,
hypertension and type 2 diabetes), dementia and to a lesser extent
with AD pathology.
It is essential to note that the major value of studying the human
brain in this way is that it is the study of the disease itself rather
than an experimental model of some aspect of the disease in the
absence of the usual comorbidities observed in the aged population
and which does not inform specifically on human AD. However,
this approach also has some limitations which have to be consid-
ered. First, inherent to the use of postmortem tissue, the study is by
nature observational and cannot demonstrate cause and effect or
any directionality. Therefore, we have investigated associations but
not mechanisms of these proteins in the context of dementia with
the neuropathological hallmarks of AD. Our study is based on the
hypothesis of the presence of a putative metaflammasome in rela-
tion with inflammation and risk factors for AD, as suggested in the
periphery (29) in experimental studies (28). Second, our analysis of
postmortem tissue may not necessarily reflect the earliest effects of
the metaflammasome proteins in dementia, hypertension or diabe-
tes but mainly the end stage of the disease; although an advantage
of the population-based CFAS approach is that it includes the full
spectrum of cognition from unimpaired to frank dementia.
Other limitations include that the information on hypertension
and diabetes is self-reported to CFAS by the participants or carers
rather than obtained from the medical records, and the potentially
confounding effects of medication taken in relation to the above
comorbidities. To mitigate these limitations, the discussion of the
findings has been based on the sustained significance after sensitiv-
ity analysis or adjusted multiple comparisons as an indication of
the robustness of the relationship.
Table 5. Weighted multiple linear regression to analyse the
relationship between metaflammasome components and the MMSE
score.
Metaflammasome
components [load (%)] b 95%CI(b) P
IKKb 4.0 (2.8; 5.3) <0.001
IRS1 21.3 (22.0; 20.6) <0.001
JNK 22.2 (22.7; 21.6) <0.001
PKR 20.7 (21.1; 20.3) 0.001
P-value< 0.012 considered to indicate statistical significance accord-
ing to the Bonferroni’s method.
Significant positive association (dark gray); Significant negative associ-
ation (light gray).
Table 6. Weighted logistic regression to investigate the relationship between metaflammasome components and Alzheimer’s pathology
according to disease status.
Metaflammasome
components [load (%)]
Meningeal CAA Parenchymal CAA Diffuse plaques Neuritic plaques Tangles
OR [95%CI(OR)]
P
OR [95%CI(OR)]
P
OR [95%CI(OR)]
P
OR [95%CI(OR)]
P
OR [95%CI(OR)]
P
No Dementia
IKKb 0.00 (0.00; 0.02)
<0.001†
0.00 (0.00; 0.00)
<0.001
0.86 (0.51; 1.45)
0.573
2.65 (1.33; 5.31)
0.006
391.08 (135.07; 1132.32)
<0.001
IRS1 0.04 (0.02; 0.09)
<0.001
0.00 (0.00; 0.00)
<0.001
0.22 (0.15; 0.31)
<0.001†
0.49 (0.31; 0.79)
0.003†
0.77 (0.19; 3.16)
0.714
JNK 0.11 (0.06; 0.21)
<0.001
0.28 (0.14; 0.56)
<0.001
1.07 (0.88; 1.31)
0.473
0.60 (0.44; 0.81)
0.001†
0.00 (0.00; 0.02)
<0.001
PKR 0.25 (0.14; 0.44)
<0.001
1.40 (0.97; 2.03)
0.072
0.76 (0.62; 0.93)
0.008
1.10 (0.84; 1.44)
0.502
0.08 (0.05; 0.14)
<0.001
Dementia with AD pathology
IKKb 0.51 (0.26; 0.98)
0.043
1.62 (0.72; 3.64)
0.242
3.89 (1.54; 9.79)
0.004†
70.24 (27.06; 182.30)
<0.001†
5.26 (2.92; 9.48)
<0.001
IRS1 0.79 (0.45; 1.38)
0.403
1.21 (0.64; 2.30)
0.555
1.66 (0.93; 2.95)
0.087
5.07 (2.75; 9.34)
<0.001
1.34 (0.81; 2.21)
0.260
JNK 8.98 (5.66; 14.25)
<0.001†
10.93 (6.46; 18.47)
<0.001†
3.11 (1.95; 4.96)
<0.001
5.96 (3.94; 9.01)
<0.001†
1.09 (0.74; 1.61)
0.650
PKR 3.63 (2.74; 4.83)
<0.001
7.35 (5.22; 10.35)
<0.001†
4.23 (3.08; 5.82)
<0.001
1.95 (1.52; 2.49)
<0.001
1.68 (1.27; 2.21)
<0.001
P-value< 0.012 considered to indicate statistical significance according to the Bonferroni’s method.
†Significant positive association (dark gray) and significant negative association (light gray) with the relationship maintained in the sensitivity
analysis.
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Our first hypothesis was that the metaflammasome proteins were
expressed in the human brain in association with metabolic disor-
ders and AD. Immunodetection confirmed the presence in the
human brain of the four components of the metaflammasome com-
plex (ie, the phosphorylated forms of IKKb, IRS1, JNK and PKR).
Both PKR and IRS1 locations were nuclear, consistent with previ-
ous detection in AD brain (36, 37). IKKb was detected in the cyto-
plasm of neurons consistent with previous studies showing a
cytoplasmic location (38). JNK showed either a nuclear or a cyto-
plasmic location as already published, potentially underlying dis-
tinct functions of JNK based on the cell compartment (39).
The concept of the metaflammasome, analogous to the inflam-
masome, was suggested in metabolic disease. Therefore, we wanted
to know whether the expression of these four proteins was associ-
ated with metabolic disorders. Data concerning two important met-
abolic disorders known as risk factors for AD were available from
the CFAS database, hypertension and type 2 diabetes. Analysis
with regard to hypertension showed an association with the meta-
flammasome proteins with a change in the relationship pattern
according to the dementia status. A significant positive association
was detected in the participants without dementia and an inverse
association in participants with dementia and AD pathology. Sev-
eral studies have revealed a positive association between high
blood pressure in midlife (40–64 years old) and the development of
dementia (40–43), whereas only two studies supported an associa-
tion between hypertension in late-life and dementia (44, 45).
Indeed, several studies suggested that in old age, hypotension could
be a higher risk factor for AD, after adjustment for antihypertensive
drugs (45–48). The working hypothesis is that long-standing hyper-
tension may lead to severe atherosclerosis/arteriolosclerosis and
impaired cerebrovascular autoregulation, whereas a decline in
blood pressure in later life may contribute to diminished cerebral
perfusion leading to an ischaemic state and increased cerebral Ab
accumulation (42). Our findings in the CFAS cohort support this
hypothesis, that participants without dementia are more likely than
participants with dementia to have elevated high blood pressure.
Regarding type 2 diabetes, significant inverse associations were
found with the metaflammasome proteins in both cohorts, except
for JNK. Indeed for JNK, the relationship was significantly inverse
in participants without dementia and positive in participants with
dementia. Our data imply that in participants with type 2 diabetes,
a low expression of JNK is more likely to be associated with the
absence of dementia; whereas a high expression will be preferably
observed in participants with dementia and AD pathology. Experi-
mental studies have shown that: (i) inhibition of JNK in the liver
leads to a beneficial effect on insulin resistance and glucose toler-
ance (49); (ii) JNK is abnormally activated in obesity (28) and (iii)
its absence leads to a decrease in adiposity and to an improvement
in insulin sensitivity (50). These findings and our observation in
human postmortem tissue indicates that JNK could change its func-
tion in type 2 diabetes in the context of dementia.
A matrix analysis was performed to investigate whether the four
proteins were acting together as a putative complex (30). The asso-
ciations detected between the different components were either
weak or moderate. Interestingly, differences in the associations
were observed according to the dementia status. In the absence of
dementia, there was no association between IKKb and JNK;
whereas in the context of AD, a significant inverse relationship was
reported between IKKb and JNK with the loss of relationship of
IKKb with IRS1 and PKR as illustrated in Figure 2. These findings
suggest that the relationship between IKKb and other components
of the metaflammasome is unstable and potentially might change
according the brain environment. Although, our data are not con-
sistent with the concept of a metaflammasome complex as
described in the periphery, they do nevertheless support a role of
these proteins in AD. Second, the role of these proteins in AD
might be driven by the relationship between IKKb and JNK.
This finding is consistent with the observation that dementia sta-
tus and poor cognition were significantly related to the expression
of JNK, whereas the presence of IKKb was related to good cogni-
tive function and the absence of dementia. This is in accordance
with a recent study which demonstrated an increased level of JNK
in the CSF of 30 AD patients associated with the rate of their cog-
nitive decline (32). Interestingly the link between dementia and
JNK appears only among the participants with dementia and AD
pathology while the relationship was not observed within the whole
cohort of participants or within participants with non-AD dementia.
This supports the hypothesis for a specific role for JNK in AD
pathogenesis, rather than JNK being a marker of the pathological
processes associated with any form of dementia. IKKb plays a role
in the coordination of the inflammatory responses through activa-
tion of the NF-jB pathway (51). Its neuroprotective function, as
suggested by our study, supports previous in vitro findings with the
expression of neuronal NF-jB protecting against Ab toxicity (52)
and oxidative stress (53), and the inhibition of neuronal NF-jB
resulting in the loss of neuroprotection (54). Interestingly, with
regards to the two other proteins involved in the putative metaflam-
masome, IRS1 and PKR, we observed a high expression related
with worse cognition, but not with the presence of dementia (frank
dementia usually reflecting the latest stage of neurodegeneration),
perhaps implying that these components might be involved in the
earlier stages of AD or in mild cognitive impairment. This is sup-
ported by a recent study showing that mice developing insulin
resistance and increased hippocampal IRS1 following a high fat
diet had a deficiency of spatial working memory due to postsynap-
tic impairment (55), the most reliable index of cognition as
observed in postmortem and biopsy studies of AD brain (56). PKR
is a pro-apoptotic serine/threonine kinase, the activation of which
by phosphorylation initiates a cascade of neurodegenerative cellular
events leading to apoptosis (57). Assay of PKR in CSF has been
shown to predict cognitive decline (31, 58) supporting the idea of
PKR as a biomarker for AD (59).
In relation to AD pathology, among the participants without
dementia, there was either no association or a significant inverse
association between the metaflammasome proteins and AD neuro-
pathology. In contrast, in the participants with dementia and AD
pathology, the metaflammasome proteins were associated with AD
pathology, especially strongly for IKKb and plaques, and for JNK
with CAA and neuritic plaques. The hypothesis of a metaflamma-
some is based on the concept that failure of endoplasmic reticulum
function (due to accumulation of newly synthesized unfolded pro-
teins) results in the activation of an unfolded protein response and
upregulated inflammation (30). Our data in part appear to support
this concept as in AD the accumulation of Ab and Tau might lead
to an unfolded protein response and inflammation, hence precipitat-
ing neurodegeneration. Interestingly, IRS1 was inversely associated
with plaques in the participants without dementia and showed no
significant relationship with AD pathology in the participants with
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dementia and AD pathology, therefore re-enforcing the idea of an
early role of IRS1 in AD pathogenesis. The only observed signifi-
cant association maintained after the sensitivity analysis between
PKR and AD pathology was with parenchymal CAA in the partici-
pants with dementia and AD pathology. In AD, PKR partially colo-
calises with phosphorylated tau (36), and thus, identifies neurons
susceptible to neurodegeneration and is generally considered as a
marker of early neurodegeneration (60). The relationship between
PKR and CAA might reflect neuronal death associated with Ab
accumulation in the vasculature. IKKb is associated with good cog-
nition and its relationship with plaques in the participants with
dementia and AD pathology raises the question of the neurotoxicity
of fibrillary Ab (61, 62). It is important to note that in the partici-
pants without dementia, the relationship between IKKb and tangles
was not sustained after the sensitivity analysis, despite the high
odds ratio (391), due to the extremely low prevalence of tangles in
this cohort. The association of JNK with CAA and neuritic plaques
reflects that both features are associated with neurodegeneration,
cognitive decline and dementia (63). Recently, increased JNK
expression was observed in the brains of AD patients associated
with amyloid pathology (32). Overall, the findings support the
hypothesis that the cerebral metaflammasome proteins might be
involved in AD pathogenesis; mainly in relation to the Ab peptide
rather than tau protein, as the significant relationships observed
with tangles were not maintained in the sensitivity analysis.
Interestingly, the expression of the components of the metaflam-
masome is independent of the APOE gene polymorphism, the main
risk factor for AD (64).
Overall, our study supports a role for these four kinases in the
human AD brain, but the formation of a metaflammasome complex
as suggested by the experimental studies remains questionable.
Intriguingly, the effect appears to be led by the relationship
between IKKb and JNK. This could explain the difference
observed in the expression of the metaflammasome regarding
dementia, cognition and hypertension. This supports previous stud-
ies in which a pro-survival mechanism of the NF-jB pathway, by
suppressing apoptosis through the inhibition of JNK signaling was
described (65–67), with the IKKb/NF-jB pathway and JNK sig-
naling leading to opposite roles during apoptosis with the antiapop-
totic function mediated through the attenuation of JNK activity
(68). Our data in the human brain support the exploration of the
use of inhibitors of kinase, such as JNK inhibitors, currently devel-
oped for B cell-related haematological cancers as potential drugs
for AD.
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